FINWIRES · TerminalLIVE
FINWIRES

IonQ Continues to Beat Revenue Guidance, Qubit Milestone on Track, Morgan Stanley Says

By

-- IonQ (IONQ) continues to beat quarterly revenue guidance, with momentum remaining strong and the company's 256-qubit milestone still on track, Morgan Stanley said in a Thursday note.

IonQ beat revenue guidance for the fourth straight quarter, including a 31% beat in Q1, the firm said.

Morgan Stanley said the company has not been specific about the drivers of outperformance, but trends point to strong ongoing momentum.

Analysts also noted that one-third of the company's revenue came from customers who have bought more than one product, pointing to cross-selling synergies.

Morgan Stanley said 256-qubit system developments are moving through later-stage systems testing and should be ready for demonstrations by year-end, with delivery expected in H1 2027.

The firm raised its 2026 revenue estimate to $265 million from $235 million and its 2027 estimate to $401 million from $380 million.

Morgan Stanley has an equal-weight rating on IonQ and raised its price target to $48.50 from $47.

Shares of IonQ were down more than 4% in Thursday trading.

Price: $50.33, Change: $-2.25, Percent Change: -4.27%

Related Articles

Australia

CVS Health Increasingly Likely to Reach 3% Medicare Advantage Target Margin in 2028, RBC Says

CVS Health (CVS) is increasingly more likely to reach its 3% Medicare Advantage target margin in 2028, RBC Capital Markets analyst said in a note Wednesday.Analysts said the company's Q1 adjusted earnings "comfortably" beat expectations, driven by "strong" topline growth and a notable improvement in profitability in the Health Care Benefits segment.Medical costs came in below expectations and, while the company maintained its medical benefit ratio guidance for the year, it is increasingly likely to outperform, according to the note.The brokerage raised its 2026 adjusted earnings estimate for the company to $7.41 from $7.10. Analysts surveyed by FactSet expect $7.29.RBC reiterated its outperform rating on the stock and increased its price target to $107 from $93.Price: $87.01, Change: $+0.14, Percent Change: +0.17%

$CVS
Research

Research Alert: CFRA Maintains Strong Buy Rating On Shares Of Trimble Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target price to $86, from 85, on a forward P/E of 21x our 2027 EPS projection of $4.08, below historical averages. We increase our 2026 EPS projection to $3.59 from $3.52, and lift our 2027 EPS estimate to $4.08 from $4.06. TRMB reported solid Q1 beats with revenue of $939.9M, up 12% Y/Y, led by AECO at 14% organic revenue and ARR growth, Field Systems posting 12% growth, and Transportation & Logistics growing 7% despite freight market headwinds. ARR reached a record $2.435B, up 13% organically, reinforcing business model durability. Non-GAAP operating margin improved 230 bps to 25.9%, while non-GAAP gross margins expanded 180 bps to 71.0%, and we see continued margin expansion as its subscription revenues scale. We note steady execution in its core business, while building AI momentum through new products and partnerships with AI labs. Management reaffirmed its 2027 targets, supporting our positive view, though macro risks warrant monitoring.

$TRMB
Australia

Apollo Global Trades at Lower Discount Versus Peers, RBC Says

Apollo Global Management (APO) shares are trading in-line with historical average multiple and at a lower discount against its peers, RBC Capital Markets said in a Thursday note."We maintain our Sector Perform rating largely driven by relative valuation," the report said.The note said its Q1 performance was characterized by strong fee-related earnings growth, offset by weak spread-related earnings growth, driving a low adjusted net income per share growth.RBC raised its price target to $146 from $139 on rolling forward its valuation and higher estimates.Price: $127.33, Change: $-2.20, Percent Change: -1.70%

$APO